Study protocol for a randomised, double-blinded, placebo-controlled phase III trial examining the add-on efficacy, cost-utility and neurobiological effects of low-dose naltrexone (LDN) in patients with fibromyalgia (INNOVA study)

BMJ Open
06 Jan 2022
https://pubmed.ncbi.nlm.nih.gov/34992118/

Effects of low-dose naltrexone on quality of life in high-grade glioma patients: a placebo-controlled, double-blind randomized trial

Support Care Cancer
10 Jan 2022
https://pubmed.ncbi.nlm.nih.gov/35001215/

Can low-dose naltrexone relieve pain?

The Seattle times
12 Jan 2022
https://www.seattletimes.com/life/wellness/can-low-dose-naltrexone-relieve-pain/

At low doses (1 to 4.5 mg) it is prescribed to ease the pain and inflammation associated with conditions such as fibromyalgia, chronic pain syndrome, multiple sclerosis and Crohn’s disease

Scientist with son who suffers from chronic fatigue syndrome hopes research can help COVID-19 patients

Fox13 Seattle
18 March 2021
https://www.q13fox.com/news/scientist-with-son-who-suffers-from-chronic-fatigue-syndrome-hopes-research-can-help-covid-19-patients

Low-dose naltrexone for the treatment of fibromyalgia: protocol for a double-blind, randomized, placebo-controlled trial

Trials
15 November 2021
https://pubmed.ncbi.nlm.nih.gov/34781989/

LDN in Clinical Practice - Andrew McCall, MB, ChB, DFM (2021 Conference) (LDN, low dose naltrexone)

A Curious Case Study: When the only solution is Skull-Reconstruction - Elizabeth Livengood, NMD (2021 Conference) (LDN, low dose naltrexone)

SIBO - Leonard Weinstock, MD (2021 Conference) (LDN, low dose naltrexone)